Michael A. Smith serves as Chief Legal Officer at Insmed Incorporated, a global biopharmaceutical company focused on transforming the lives of patients with rare diseases. With over 25 years of experience in the pharmaceutical and biotechnology industries, Smith joined Insmed in 2018 as Senior Vice President and General Counsel before ascending to his current role in 2021. He oversees all legal, compliance, intellectual property, and regulatory affairs functions, playing a pivotal role in the company's strategic growth, including the development and commercialization of its lead product, ARIKAYCE (amikacin liposome inhalation suspension), approved for the treatment of refractory Mycobacterium avium complex lung disease. Prior to Insmed, Smith held senior legal positions at Shire plc (now Takeda), where he served as Vice President and Deputy General Counsel, managing global legal operations for rare disease and specialty therapeutics franchises. His earlier career included key roles at Wyeth (acquired by Pfizer), where he advised on mergers, acquisitions, and complex regulatory matters, and at Pfizer Inc., contributing to high-stakes litigation and corporate transactions. Smith earned his Juris Doctor from Villanova University School of Law and a Bachelor of Arts from the University of Pennsylvania, and he is admitted to the bar in multiple states. Under Smith's leadership, Insmed has navigated significant milestones, such as expanding its pipeline into other rare pulmonary disorders and forging key partnerships while maintaining robust compliance in a highly regulated industry. His expertise in FDA interactions and intellectual property strategy has been instrumental in securing orphan drug designations and advancing clinical programs, solidifying Insmed's position as an innovator in inhaled therapeutics.